In the meta-analysis, compared with placebo, HF risk showed a non-significant 10% reduction with the newer anti-hyperglycemic drugs (HR = 0.90, 0.80–1.01); use of DPP-4i and glucagon-like peptide-1-receptor-agonists GLP-1 RAs [6] was associated with nonsignificant modifications of the HF risk (+5% and −9%, respectively). Here, GLP1R is linked to hydrops fetalis.